Rebif

DRUG12 trials

Sponsors

EMD Serono, University of North Carolina, Chapel Hill, Teva Branded Pharmaceutical Products R&D, Inc., Bayer, Merck KGaA, Darmstadt, Germany

Conditions

Clinically Isolated SyndromeHealthyMultiple SclerosisRelapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 1

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

CompletedNCT02269930

BiogenMultiple Sclerosis

Start: 2014-10-31End: 2014-12-31Updated: 2015-02-02

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

CompletedNCT02359877

Start: 2014-07-31End: 2015-12-31Updated: 2017-04-10

Phase 2

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

CompletedNCT01198132

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis

Start: 2009-11-30End: 2015-11-30Updated: 2017-12-14

Phase 4

Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects

WithdrawnNCT00101959

EMD SeronoRelapsing-Remitting Multiple Sclerosis

Start: 2004-11-30Updated: 2013-08-06

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

TerminatedNCT00202995

Teva Branded Pharmaceutical Products R&D, Inc.Relapsing Remitting Multiple Sclerosis

Start: 2004-07-31End: 2007-10-31Updated: 2010-10-18

Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

CompletedNCT00317941

BayerRelapsing-remitting Multiple Sclerosis

Start: 2006-03-31End: 2008-04-30Updated: 2013-10-21

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

CompletedNCT01085318

EMD SeronoMultiple Sclerosis

Start: 2010-06-30End: 2012-03-31Updated: 2018-02-23

Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™

CompletedNCT02254304

Merck KGaA, Darmstadt, GermanyClinically Isolated Syndrome, Relapsing Multiple Sclerosis

Start: 2014-12-31End: 2016-08-20Updated: 2018-03-30

Unknown Phase

EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

CompletedNCT00137176

University of North Carolina, Chapel HillMultiple Sclerosis

Start: 2004-10-31End: 2008-10-31Target: 30Updated: 2009-06-23

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

CompletedNCT01601119

Merck KGaA, Darmstadt, GermanyRelapsing Multiple Sclerosis

Start: 2012-01-31End: 2014-07-31Updated: 2015-05-29

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

CompletedNCT02823951

IMS HEALTH GmbH & Co. OHGRelapsing-remitting Multiple Sclerosis

Start: 2016-02-29End: 2018-02-28Updated: 2018-03-01

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

TerminatedNCT02949908

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis

Start: 2017-02-09End: 2017-08-25Updated: 2019-01-18

Related Papers

Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly

UNC Libraries2021-06-24

Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study

UNC Libraries2020-11-07

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

UNC Libraries2019-08-18

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).

2019-08-0668 citations

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

2015-11-1112 citations

Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly.

2015-03-053 citations

Associations Between Changes in Ferritin Levels and Susceptibility-Weighted Imaging Filtered Phase in Patients with Relapsing-Remitting Multiple Sclerosis over Six Months Therapy with Interferon Beta-1a (P6.115)

Neurology2014-04-08

Changes in Immunological Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Interferon Beta-1a (P4.132)

Neurology2014-04-08

Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a (P3.146)

Neurology2014-04-08

Correlations between Immunological Biomarkers and Conventional and Advanced MRI Measures Following Interferon Beta-1a Treatment for Relapsing-Remitting Multiple Sclerosis (P3.147)

Neurology2014-04-08

Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study

PLoS ONE2014-03-1319 citations